Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABBV-2294 (Combination of ABBV-722 and Upadacitinib) in Adult Patients With Systemic Sclerosis

NCT07933211 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABBV-2294 (Combination of ABBV-722 and Upadacitinib) in Adult Patients With Systemic Sclerosis
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
December 11, 2026
Completion date
June 30, 2035
Enrollment
580 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis

Arms

As registered; 5 arms.

  • Part 1: Double Blind Placebo Controlled Arm 1 ExperimentalABBV-722, Upadacitinib

    Participants are randomized to receive Dose 1: ABBV-2294 (combination of ABBV-722 and upadacitinib)

  • Part 1: Double Blind Placebo Controlled Arm 2 ExperimentalABBV-722, Upadacitinib

    Participants are randomized to receive Dose 2: ABBV-2294 (combination of ABBV-722 and upadacitinib)

  • Part 1: Double Blind Placebo Controlled Arm 3 ExperimentalABBV-722

    Participants are randomized to receive ABBV-722

  • Part 1: Double Blind Placebo Controlled Arm 4 ExperimentalUpadacitinib

    Participants are randomized to receive upadacitinib

  • Part 1: Double Blind Placebo Controlled Arm 5 ExperimentalPlacebo for ABBV-722, Placebo for Upadacitinib

    Participants are randomized to receive placebo

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Part 1 & Part 2: Achievement of Revised Composite Response Index in Systemic Sclerosis (rCRISS)-25 At Week 52

    The rCRISS is a 2-step process wherein participants are determined to be considered as a responder or a non-responder. The first step of the rCRISS accounts for worsening or incident cases of any internal organ involvement. If the participant meets any of the Step 1 criteria, they are considered a non-responder in the trial afterwards. Step 2 includes 5 core set measures. The FVC% is evaluated to see if the change is at least 5%. The other 4 core set measures (modified Rodnan skin score (mRSS), Health Assessment Questionnaire Disability Index (HAQ-DI), Patient Global Assessment (PGA) and clinician global assessment) are evaluated for change of at least 25%. A responder is a participant who has relative improvement on at least 2 of the 5 core set measures without worsening on more than 1 core set measure

  • Part 1 & Part 2: Number of Participants Experiencing Adverse Events Up to 112 Weeks

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Lead sponsor's other trials

AbbVie, most recent start first.

Similar trials

Same condition (Scleroderma, Systemic) and phase, most recent start first.